Parkin Protein: The Missing Link Between Cardiovascular and Parkinson’s Disease
Publisher
Springer Singapore
Reference102 articles.
1. Chen Y, Dorn GW (2013) PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340(6131):471–475.
https://doi.org/10.1126/science.1231031
2. Dorn GW II (2016) Central Parkin: the evolving role of Parkin in the heart. Biochim Biophys Acta (BBA) Bioenerg 1857(8):1307–1312
3. Swallow DMA, Lawton MA, Grosset KA et al (2016) Statins are underused in recent-onset Parkinson’s disease with increased vascular risk: findings from the UK Tracking Parkinson’s and Oxford Parkinson’s Disease Centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry 87:1183–1190
4. Günaydın ZY, Özer FF, Karagöz A, Bektaş O, Karataş MB, Vural A, Bayramoğlu A, Çelik A, Yaman M (2016) Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment. J Geriatr Cardiol 13(1):75–80.
https://doi.org/10.11909/j.issn.1671-5411.2016.01.003
5. Jones JD, Tanner JJ, Okun M, Price CC, Bowers D (2017) Are Parkinson’s patients more vulnerable to the effects of cardiovascular risk: a neuroimaging and neuropsychological study. J Int Neuropsychol Soc. Author manuscript; available in PMC 2017 Dec 14. Published in final edited form as: J Int Neuropsychol Soc. 2017 Apr; 23(4): 322–331. Published online 2017 Feb 6. doi: 10.1017/S1355617717000017